Biopharmaceutical wholesalers in Japan play broader roles than their counterparts overseas. Beyond logistics and distribution, wholesalers perform a variety of tasks related to finance, safety, and commercialization. Such functions are typically cited as justification for various fees, rebates, and allowances…
ACADEMIA
Tokushukai Weighs Switches from Nichi-Iko Products after Biz Suspension Order
Major hospital chain Tokushukai has started considering moving away from products manufactured by Nichi-Iko Pharmaceutical as clinicians and patients harbor growing quality concerns for its drugs after the top generic maker was slapped with a business suspension order. Tokushukai uses…
To read the full story
Related Article
ACADEMIA
- Osteoporosis Society Greatly Alarmed by Vitamin D3 Analog Shortages, Might Take Further Measures
July 29, 2021
- Scientific Societies Propose Measures for Osteoporosis Treatment amid Shortages of Vitamin D Analogs
July 21, 2021
- Japan KOL Pins Hopes on Pemazyre as 1st Biliary Tract Cancer Drug in 9 Years
July 16, 2021
- Japan Needs Discussions on Target Population of Aducanumab: Clinician
July 12, 2021
- 11% of Japanese COVID-19 Vaccine Hesitant, 74% Fret Adverse Reactions: Survey
July 6, 2021
With its first “off-year” drug price revision implemented this April, Japan has now wrapped up all the reform plans agreed upon by four state ministers in 2016 for pharmaceutical pricing. As the government has provided no further mid-term vision for…
The average ratio of female employees at managerial posts stood at just 12.5% at pharmaceutical companies operating in Japan, a Jiho survey revealed. While foreign drug makers had an average 25.0%, the ratio came to as low as 9.8% for…
Biogen’s controversial Alzheimer’s drug aducanumab was filed for Japanese regulatory approval in December. If approved, it will be the first…
Japan’s key reimbursement policy panel on December 20 approved an outline of its FY2020 drug pricing reform next April, with…
Japan will go ahead with the introduction of a cost-effectiveness assessment (CEA) scheme for drugs and medical devices in April…